The Atom Is Carbon Or The Chain Consists Of Carbons Patents (Class 548/524)
  • Patent number: 10676368
    Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: June 9, 2020
    Assignee: ExxonMobil Research & Engineering Company
    Inventors: Allen W. Burton, Eugene Terefenko, Mobae Afeworki
  • Patent number: 10597300
    Abstract: A novel synthetic crystalline material, EMM-28, can be synthesized in the presence of an organic structure directing agent (Q) selected from one or more of the following dications: EMM-28 may be used in organic compound conversion reactions and sorptive processes.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: March 24, 2020
    Assignee: EXXONMOBIL RESEARCH AND ENGINEERING COMPANY
    Inventors: Kirk D. Schmitt, Hilda B. Vroman, Allen W. Burton, Michael A. Marella, Ross Mabon, Simon C. Weston
  • Patent number: 10576464
    Abstract: The disclosure is related to various modified EMM-23 materials, processes, and uses of the same.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: March 3, 2020
    Assignee: EXXONMOBIL RESEARCH AND ENGINEERING COMPANY
    Inventors: Allen W. Burton, Eugene Terefenko, Randall J. Meyer, Hilda B. Vroman
  • Patent number: 9238675
    Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: January 19, 2016
    Assignee: GENENTECH, INC.
    Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
  • Publication number: 20150133430
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventors: Qing XU, Zhe LI
  • Publication number: 20150111875
    Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
  • Publication number: 20150073155
    Abstract: Provided is a multi-arm polyethylene glycol derivative having a narrow molecular weight distribution. A multi-arm polyethylene glycol derivative represented by the formula (1): m[Z—Yn?CH2CH2O??X—O-L-O—X??OCH2CH2?nY—Z]m??(1) wherein, L represents a group selected from a linear or branched alkylene, arylene, or cycloalkylene group having two or more carbon atoms and combinations thereof, which may have an ether bond in a chain; X represents a dehydroxylation residue of a linear sugar alcohol having 5 or 7 carbon atoms; m is the number of polyethylene glycol chains bonded to X and represents 4 or 6; n is the average addition molar number of oxyethylene groups and n represents an integer of 3 to 600; Y represents a single bond or an alkylene group which may have an ester bond, a urethane bond, an amide bond, an ether bond, a carbonate bond, a secondary amino group, a urea bond, a thioether bond or a thioester bond in a chain or at an end; and Z represents a chemically reactive functional group.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 12, 2015
    Applicant: NOF CORPORATION
    Inventors: Hiroki Yoshioka, Midori Hirai, Hitoshi Nakatsuhara, Yuji Yamamoto
  • Publication number: 20140336394
    Abstract: A new molecular sieve material is designated as EMM-23 and has, in its as-calcined form, an X-ray diffraction pattern including the following peaks in Table 1: TABLE 1 d-spacing (?) Relative Intensity [100 × I/I(o)] 17.5-16.3 60-100 10.6-10.1 5-50 9.99-9.56 20-70? 6.23-6.06 1-10 5.84-5.69 1-10 5.54-5.40 1-10 4.29-4.21 1-10 3.932-3.864 1-10 3.766-3.704 5-40 3.735-3.674 1-10 3.657-3.598 1-10 3.595-3.
    Type: Application
    Filed: July 24, 2012
    Publication date: November 13, 2014
    Applicant: ExxonMobil Chemical Company - Law Technology
    Inventors: Allen W. Burton, Karl G. Strohmaier, Hilda B. Vroman
  • Publication number: 20140316088
    Abstract: The present invention provides, among other things, novel compounds and methods for metathesis reactions. In some embodiments, a provided compound has the structure of formula I or II. In some embodiments, the present invention provides compounds and methods for Z-selective olefin metathesis.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 23, 2014
    Applicant: Massachusetts Institute of Technology
    Inventors: Richard Royce Schrock, Michael R. Reithofer
  • Publication number: 20140275008
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Inventors: Qing Xu, Zhe Li
  • Publication number: 20140249320
    Abstract: The present invention relates to pyrrolidin-2-ones according to the formula (1), or salts thereof, wherein R1 is hydrogen or a nitrogen protecting group, methods for their preparation and their use in the preparation of NEP-inhibitors, particularly in the preparation of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.
    Type: Application
    Filed: March 25, 2014
    Publication date: September 4, 2014
    Inventors: David Hook, Thomas Ruch, Bernard Riss, Bernhard Wietfeld, Gottfried Sedelmeier, Matthias Napp, Markus Bänziger, Steven Hawker, Lech Ciszewski, Liladhar Murlidhar Waykole
  • Publication number: 20140213588
    Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments. The disclosure also provides a novel method of treating diseases or conditions related to the activity of endothelial lipase by use of compounds according to Formula (II): as defined in the specification and compositions comprising any of the compounds.
    Type: Application
    Filed: September 26, 2012
    Publication date: July 31, 2014
    Applicant: Bristol-Myers Squibb Company
    Inventors: Lynn Abell, Leonard Adam, Cullen L. Cavallaro, Heather Finlay, Todd J. Friends, Jon J. Hangeland, Ji Jiang, R. Michael Lawrence, Jennifer X. Qiao, Carol Hui Hu, Tammy C. Wang
  • Publication number: 20140199601
    Abstract: The present invention aims to provide an additive for a non-aqueous electrolyte solution with excellent storage stability capable of forming a stable SEI on the surface of an electrode to improve cell performance such as a cycle performance, a discharge/charge capacity, and internal resistance, when the additive is used for electrical storage devices such as non-aqueous electrolyte solution secondary cells and electric double layer capacitors. The present invention also aims to provide a non-aqueous electrolyte solution containing the additive for a non-aqueous electrolyte solution and to provide an electrical storage device using the non-aqueous electrolyte solution.
    Type: Application
    Filed: July 6, 2012
    Publication date: July 17, 2014
    Applicant: SUMITOMO SEIKA CHEMICALS CO., LTD.
    Inventors: Tomohiro Onozuka, Shohei Fujimoto, Koji Fujita
  • Publication number: 20140179753
    Abstract: The present invention relates to compounds from Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: March 5, 2014
    Publication date: June 26, 2014
    Applicant: Simpson Biotech Co., Ltd.
    Inventors: Masao HATTORI, Ali EL-HALAWANY, Megumi MIZUNO, Chia-Chin SHEU
  • Publication number: 20140142082
    Abstract: The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 13, 2012
    Publication date: May 22, 2014
    Applicant: PHENEX PHARMACEUTICALS AG
    Inventors: Christoph Steeneck, Olaf Kinzel, Christian Gege, Gerald Kleymann, Thomas Hoffmann
  • Publication number: 20140118816
    Abstract: Surfactants are provided that have a hydrophobic tail portion and a hydrophilic head portion. The hydrophilic head portion includes a terminal dialkyl-substituted tertiary amine or a terminal cycloalkyl-substituted tertiary amine. Also provided are pigment-based inks employing the surfactant, a combination of an electronic display and the pigment-based inks, and a process for reducing conductivity in primary amine-based surfactants and improving reliability of electronic inks employing such surfactants.
    Type: Application
    Filed: June 10, 2011
    Publication date: May 1, 2014
    Inventors: Zhang-Lin Zhou, Qin Liu, Mary Elizabeth Parent
  • Publication number: 20140107336
    Abstract: The present invention relates to a novel class of tri-aryl compounds, compositions comprising the same and processes for the preparation thereof.
    Type: Application
    Filed: November 1, 2013
    Publication date: April 17, 2014
    Applicant: BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY
    Inventors: Esther PRIEL, Aviv GAZIT, Shimon SLAVIN, Sara YITZCHAK
  • Publication number: 20140039181
    Abstract: The invention relates to a method for producing a N-substituted amine compound by catalyzed alkylation. The method uses amine and alcohol or two kinds of amines as the reaction materials, employs composite metal oxides catalyst at a reaction temperature of 80-180° C. to catalyze the reaction for 6-36 hours, so as to produce the N-substituted amine compound. The reaction condition of the method of the invention is relatively moderate, using a catalyst made of cheap non-noble metals, which is non-caustic and easy to be separated and reused. The reaction does not need any medium and has relatively high conversion rate and selectivity.
    Type: Application
    Filed: December 28, 2012
    Publication date: February 6, 2014
    Applicant: Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences
    Inventor: Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences
  • Patent number: 8637611
    Abstract: The invention is based on the discovery that a remarkable improvement in the performance of maleimide thermosets can be achieved by incorporating amide-extended maleimides into an adhesive formulation. Amide-extended maleimides described herein can be used to toughen bismaleimide thermosetting materials without sacrificing any thermal stability. Amide-extended maleimides are readily prepared by reacting a bismaleimide with an appropriate amine via the well-known Michael addition reaction. Acylation of the resulting secondary amines provides the amide-extended maleimide. The acylating agent can also be used to introduce polymerizable functional groups into the backbones of these thermoset monomers. Amide-extended acrylate and methacrylate monomers can also be prepared.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: January 28, 2014
    Assignee: Designer Molecules, Inc.
    Inventor: Stephen M Dershem
  • Publication number: 20140011721
    Abstract: The present disclosure relates to a compound of the formula I or a tribologically acceptable salt, solvate, hydrate, or proadditive thereof, wherein R1, R2 and R4 are as defined herein. Such novel pyrrolidine, or succinimide, derivatives may be useful as friction modifiers in lubricant compositions. This disclosure also relates to a method of using such friction modifier compounds in lubricating fluid formulations to lubricate machine parts, including gear, axle, engine, and transmission parts, and to lubricant compositions containing such friction modifier compounds.
    Type: Application
    Filed: September 6, 2013
    Publication date: January 9, 2014
    Applicant: Afton Chemical Corporation
    Inventors: Roger M. SHEETS, Nubar Ozbalik
  • Publication number: 20130253186
    Abstract: Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.
    Type: Application
    Filed: May 10, 2013
    Publication date: September 26, 2013
    Applicant: Amgen Inc.
    Inventors: Jennifer R. Allen, Daniel B. Horne, Essa Hu Harrington, Matthew R. Kaller, Holger Monenschein, Thomas T. Nguyen, Andreas Reichelt, Robert M. Rzasa
  • Publication number: 20130231332
    Abstract: The present invention relates to compositions and methods for the treatment of infection by enveloped viruses, such as Ebola and Lassa fever viruses.
    Type: Application
    Filed: September 1, 2011
    Publication date: September 5, 2013
    Inventors: James Cunningham, Kyungae Lee, Tao Ren, Kartik Chandran
  • Publication number: 20130225649
    Abstract: The present invention relates to compounds from Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection.
    Type: Application
    Filed: October 17, 2012
    Publication date: August 29, 2013
    Applicant: SIMPSON BIOTECH CO., LTD.
    Inventor: SIMPSON BIOTECH CO., LTD.
  • Publication number: 20130217665
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: February 14, 2013
    Publication date: August 22, 2013
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: HOFFMANN-LA ROCHE INC.
  • Publication number: 20130184249
    Abstract: The present invention relates to compounds of formula wherein R1, R2, R3, R4, Z, and n are as defined herein or to a pharmaceutically active salt thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
    Type: Application
    Filed: February 28, 2013
    Publication date: July 18, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.
  • Patent number: 8481722
    Abstract: Polyionic liquid salts are provided comprising polycationic or polyanionic molecules. Further provided are solvents comprising one or more polyionic liquid salts, and the use of such polyionic liquid salts as stationary phases in gas chromatography, and as a reagent in electrospray ionization-mass spectrometry (ESI-MS).
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: July 9, 2013
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Daniel W Armstrong, Junmin Huang
  • Publication number: 20130152314
    Abstract: The invention relates to a composition for dyeing keratin materials, and in particular human keratin fibres such as the hair, comprising at least one 2-pyrrolidone functionalized in the 4 position with an ester or amide radical, and at least one hydrophobic direct dye or a pigment; a dyeing process using this composition. Similarly, the invention relates to the use of the said pyrrolidone combined with a direct dye or a pigment for dyeing keratin materials, and especially to the use of the said pyrrolidone for improving the colour uptake onto the fibres of direct dyes that are sparingly soluble or insoluble in aqueous-alcoholic supports. The invention also relates to novel pyrrolidone derivatives. The present invention makes it possible in particular to obtain direct dyeing on keratin materials that is fast, resistant to washing, chromatic and powerful.
    Type: Application
    Filed: June 8, 2011
    Publication date: June 20, 2013
    Applicant: L'OREAL
    Inventors: Stéphane Sabelle, Madeleine Leduc, Christian Blaise
  • Patent number: 8431721
    Abstract: The invention relates to compounds of the structure of formula I and II: where X is selected from the group consisting of O, S and NH; Y, A and B are independently selected from the group consisting of N and CH; D, E and F are independently selected from the group consisting of CH, N, O and S; the symbol represents a single or a double bond; and R1, R2 and R3 are independently selected from the group consisting of H, electron withdrawing groups and electron releasing groups. In other embodiments, the compounds are used as oxygen scavengers and in barrier compositions and articles.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: April 30, 2013
    Assignee: Constar International, Inc.
    Inventors: Girish Nilkanth Deshpande, Paul David Weipert, Michael W. Ensley
  • Publication number: 20120289710
    Abstract: The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a g-amino-d-biphenyl-a-methylalkanoic acid, or acid ester, backbone, such as N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.
    Type: Application
    Filed: January 21, 2011
    Publication date: November 15, 2012
    Inventors: David Hook, Jianguang Zhou, Yunzhong Li
  • Publication number: 20120252743
    Abstract: The invention provides methods of making and using compounds of the formula: or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selected from the group consisting of CH or N; R1 is selected from the group consisting of —CH2NH2, and R2 is selected from the group consisting of —H, —OH, —NH2 and acetyl; R3 is selected from the group consisting of —H, benzyloxycarbonyl and benzylsulfonyl; and R4 is selected from the group consisting of —OH, wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of —O—, —S—, —S(?O)—, —SO2—, methylene, —CH(OH)—, —CH(NH2)—, —CH(CH2—OH)—, —CH(CH2—NH2)— or —N(R6)—, R5 is selected from the group consisting of —H or a simple (C1-C3) alkyl and R6 is selected from the group consisting of —H, a simple (C1-C3) alkyl or a simple (C1-C3) acyl.
    Type: Application
    Filed: December 21, 2011
    Publication date: October 4, 2012
    Applicant: The Medicines Company (Leipzig) GmbH
    Inventors: Peter Herold, Stjepan Jelakovic, Mohammed Daghish, Claudia Reichelt, Alexander Schulze, Andrea Schweinitz, Friedrich-Alexander Ludwig, Adel Rafai Far, Ting Kang
  • Publication number: 20120225055
    Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.
    Type: Application
    Filed: March 1, 2011
    Publication date: September 6, 2012
    Inventors: Tejinder Kaur BHINDER, Susannah Karen Ford, Volker Germaschewski, Alan Peter Lewis, Mark Brian Pepys
  • Publication number: 20120146264
    Abstract: A resin composition for laser engraving is provided that includes a low molecular weight compound containing at least one type of polymerizable group selected from the group consisting of an ethylenically unsaturated group, an epoxy group, an oxetanyl group, a hydrolyzable silyl group, and a silanol group and further containing a sulfonamide group, a low molecular weight compound containing a residue selected from the group consisting of a maleimide group, a succinimide group, and a phthalimide group, or a polymer compound containing a constituent unit derived from a compound containing a maleimide group or a constituent unit containing a sulfonamide group.
    Type: Application
    Filed: December 9, 2011
    Publication date: June 14, 2012
    Applicant: FUJIFILM CORPORATION
    Inventor: Takashi KAWASHIMA
  • Publication number: 20120142916
    Abstract: The present invention relates to pyrrolidin-2-ones according to the formula (1), or salts thereof, wherein R1 is hydrogen or a nitrogen protecting group, methods for their preparation and their use in the preparation of NEP-inhibitors, particularly in the preparation of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.
    Type: Application
    Filed: December 21, 2011
    Publication date: June 7, 2012
    Inventors: David Hook, Thomas Ruch, Bernhard Riss, Bernhard Wietfeld, Gottfried Sedelmeier, Matthias Napp, Markus Bänziger, Steven Hawker, Lech Ciszewski, Liladhar Murtidhar Waykole
  • Publication number: 20120083603
    Abstract: Polyionic liquid salts are provided comprising polycationic or polyanionic molecules. Further provided are solvents comprising one or more polyionic liquid salts, and the use of such polyionic liquid salts as stationary phases in gas chromatography, and as a reagent in electrospray ionization-mass spectrometry (ESI-MS).
    Type: Application
    Filed: December 13, 2011
    Publication date: April 5, 2012
    Applicant: Sigma-Aldrich Co. LLC
    Inventors: Daniel W. Armstrong, Junmin Huang
  • Publication number: 20120025183
    Abstract: Provided is an acenaphtho[1,2-k]benzo[e]acephenanthrene derivative represented by general formula (1): wherein R1 to R16 are each independently selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group; and at least one of R1 to R8 and R10 to R15 is selected from a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group.
    Type: Application
    Filed: April 22, 2010
    Publication date: February 2, 2012
    Applicant: CANON KABUSHIKI KAISHA
    Inventors: Jun Kamatani, Takayuki Horiuchi, Naoki Yamada, Akihito Saitoh
  • Patent number: 8097721
    Abstract: Polyionic liquid salts are provided comprising polycationic or polyanionic molecules. Further provided are solvents comprising one or more polyionic liquid salts, and the use of such polyionic liquid salts as stationary phases in gas chromatography, and as a reagent in electrospray ionization-mass spectrometry (ESI-MS).
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: January 17, 2012
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Daniel W. Armstrong, Junmin Huang
  • Publication number: 20120010235
    Abstract: Compounds of formula and enantiomers and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control, amelioration or prevention of cancer.
    Type: Application
    Filed: June 30, 2011
    Publication date: January 12, 2012
    Inventors: Xin-Jie Chu, Qingjie Ding, Nan Jiang, Jin-Jun Liu, Tina Morgan Ross, Zhuming Zhang
  • Patent number: 8092891
    Abstract: A cyanine compound is represented by: wherein, R11 and R12 each independently represent a hydrogen atom, a hydroxyl group, a halogen atom, a nitro group, a cyano group, an organic group having 1 to 30 carbon atoms, or a group represented by the following general formula (II), (II?), or (III); R13 and R14 each independently represent a hydrogen atom, an organic group having 1 to 30 carbon atoms, or a substituent represented by the following general formula (III); R11 and R12 may be connected together to form a ring structure; R19 represents a hydrogen atom or an organic group having 1 to 30 carbon atoms; R13 and R14 may be connected together to form a heterocycle; N—R13 may be connected together with a methylene group in a polymethine chain to form a heterocycle; Z00 is an organic group having 1 to 10 carbon atoms; m is 0 or 1; s is 2 to 8; Anq? represents an anion having a valence of q; q is 1 or 2; and p represents a coefficient for maintaining charge neutrality.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: January 10, 2012
    Assignee: Adeka Corporation
    Inventor: Satoshi Yanagisawa
  • Publication number: 20110301159
    Abstract: The disclosure relates to novel compounds that are capable of modulating Jak2 kinase activities, compounds that have therapeutic use in treating or preventing a subject suffering from or susceptible to a Jak2 mediated disease or disorder, and methods of use and compositions thereof.
    Type: Application
    Filed: December 9, 2009
    Publication date: December 8, 2011
    Applicants: UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Peter P. Sayeski, Gyorgy M. Keseru, Kirpal Bisht
  • Patent number: 8058293
    Abstract: Disclosed herein are compounds of formula (I) wherein R1, R2, R3, R25a, R26a, X, and n are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions are also described.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: November 15, 2011
    Assignee: Abbott Laboratories
    Inventors: Teodozyj Kolasa, Jennifer M. Frost, Meena V. Patel, Steven P. Latshaw, Arturo Perez Medrano, Xueqing Wang, Karin Rose Marie Tietje, Sridhar Peddi, William A. Carroll
  • Publication number: 20110269652
    Abstract: The invention relates to gemini surfactants of formula IA wherein A is a core derived from an organic polyhydroxy compound; R1 and R2 are each independently a hydrophobic group; and R3 and R4 are each independently a surfactant head group. Such surfactants can be used as components of fluids used in the petroleum industry or used in formulating cleansing compositions or detergent compositions.
    Type: Application
    Filed: October 29, 2009
    Publication date: November 3, 2011
    Applicant: ST. FRANCIS XAVIER UNIVERSITY
    Inventors: D. Gerrard Marangoni, T. Bruce Grindley, Nusrat Jahan, Christian Petropolis, Thomas Tran, Nawal Paul
  • Publication number: 20110263428
    Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
    Type: Application
    Filed: July 1, 2009
    Publication date: October 27, 2011
    Applicant: SYNGENTA CROP PROTECTION, INC.
    Inventors: Stephane Andre Marie Jeanmart, Russell Colin Viner, John Benjamin Taylor, William Guy Whittingham, Jeffrey Steven Wailes, Sarah Margaret Targett, Christopher John Mathews, Mangala Govenkar, Matthew Robert Cordingley, Claire Janet Russell, Melloney Tyte
  • Publication number: 20110230419
    Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, that bind to Inhibitor of Apoptosis Proteins (IAPs). The compounds of the invention may be used as diagnostic and therapeutic agents in the treatment of proliferative diseases, such as cancer, for promoting apoptosis in proliferating cells, and for sensitizing cells to inducers of apoptosis. The present invention furthermore provides a polymeric compound of formulas (VI) or (VII), comprising either at least two monomeric units of compounds of formula (I), or at least one monomeric unit of a compound of formula (I) and an entity E. The present invention further relates to pharmaceutical compositions comprising said compounds of formulas (I), (VI), and (VII) and the use of said compounds in medicine.
    Type: Application
    Filed: June 16, 2009
    Publication date: September 22, 2011
    Applicant: Nuevolution A/S
    Inventors: Mikkel Dybro Lundorf, Kim Birkebaek Jenson, Sanne Schrøder Glad, Alek Haahr Gouliaev, Anette Holtmann, Michael Anders Godskesen
  • Patent number: 8008301
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine—H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: August 30, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Terry Patrick Finn, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Publication number: 20110144103
    Abstract: The present invention relates to substituted pyrrole compounds and compositions comprising substituted pyrrole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted pyrrole compound of the invention, or a pharmaceutical composition comprising such a compound.
    Type: Application
    Filed: June 4, 2009
    Publication date: June 16, 2011
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Publication number: 20110144081
    Abstract: The present invention relates to compounds of formula wherein R1, R2, R3, R4, Z, and n are as defined herein or to a pharmaceutically active salt thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
    Type: Application
    Filed: December 7, 2010
    Publication date: June 16, 2011
    Inventors: Henner Knust, Andreas Koblet, Matthias Nettekoven, Hasane Ratni, Claus Riemer, Walter Vifian
  • Publication number: 20110118475
    Abstract: The current application relates to a metal catalyst of formula (I): M[ADC][X]n, wherein M is a metal, ADC is a chiral acyclic diaminocarbene ligand, and X is a neutral or anionic ligand. The ADC ligand is prepared from the corresponding chiral formamidium salt precursor. The metal catalyst is used for asymmetric organic synthesis reactions such as hydrosilations, hydrogenations, conjugate additions, and cross-couplings.
    Type: Application
    Filed: July 7, 2009
    Publication date: May 19, 2011
    Inventors: Avinash N. Thadani, Rukundo Ntaganda, Mira M. Beshai
  • Patent number: 7910106
    Abstract: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: March 22, 2011
    Assignee: Pentraxin Therapeutics Ltd.
    Inventor: Mark B. Pepys
  • Publication number: 20110041263
    Abstract: The invention relates to the dyeing of keratin fibres using azomethine direct dyes or precursors of azomethine dyes obtained from 2-alkylresorcinols. The invention relates to a dye composition comprising at least one azomethine direct dye or pre-cursor of an azomethine direct dye, to a process for dyeing keratin fibres, using the said composition, and to their uses in the dyeing of keratin fibres. This composition allows a particularly stable and fast coloration to be obtained.
    Type: Application
    Filed: December 9, 2008
    Publication date: February 24, 2011
    Inventors: Madeleine Leduc, Eric Metais, Stéphane Sabelle, Christophe Rondot
  • Publication number: 20110017908
    Abstract: Dicationic liquid salts and methods of using such dicationic liquid salts in techniques such as ESI-MS are provided.
    Type: Application
    Filed: February 17, 2009
    Publication date: January 27, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventor: Armstrong W. Daniel